

Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights

BRISBANE, Calif.--(BUSINESS WIRE)--May 1, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Wednesday, May 8, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2019, and recent operational highlights.

To access the live call by phone, dial (877) 497-1438 (domestic) or (262) 558-6296 (international) and enter the passcode 5667779. To access a live or recorded webcast of the call, please visit the Investor Relations section of the Aimmune Therapeutics website at www.aimmune.com. The recorded webcast will be available for approximately 30 days following the call.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company's **Characterized Oral Desensitization ImmunoTherapy** (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune's first investigational biologic product, AR101, is being developed as a treatment to reduce the risk of anaphylaxis following accidental exposures to peanut. The BLA for AR101 is under review by the FDA, which in 2015 granted AR101 Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4 to 17 years of age. Aimmune expects to file for marketing approval of AR101 in Europe in mid-2019. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see www.aimmune.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190501005361/en/>

Source: Aimmune Therapeutics, Inc.

Investors

Eric Bjerkholt, 650-376-5582
ebjerkholt@aimmune.com

Media

Jerica Pitts, 312-858-3469
jpitts@w2ogroup.com

<https://swkhold.investorroom.com/2019-05-01-Aimmune-Therapeutics-to-Host-Conference-Call-and-Webcast-to-Discuss-First-Quarter-2019-Financial-Results-and-Recent-Operational-Highlights>